PT-141
Bremelanotide melanocortin receptor agonist studied in vitro.
Specification
- Catalogue ID: SP130
- Listed purity specification: 99.5%
- Formulation: Lyophilized
- Quantity: 10mg / Vial
- Price: £49.00
Melanocortin receptor research · MC1-R / MC4-R pharmacology
PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist with a lactam-cyclised backbone. Vivera supplies it strictly as a research reagent.
In receptor-binding and cell-based assays, PT-141 acts as a non-selective agonist at melanocortin receptors MC1-R, MC3-R, MC4-R, and MC5-R. Functional potency studies show highest activity at MC1-R and MC4-R; these receptors signal through Gαs-coupled adenylyl cyclase activation, increasing intracellular cAMP.
The compound is used as a tool compound in melanocortin-receptor pharmacology research, specifically in comparative studies of receptor-subtype selectivity, ligand-receptor docking, and structure-activity relationship (SAR) investigations within the MSH/ACTH-derived peptide class.
No physiological or therapeutic properties are claimed; supplied strictly as a research reagent for in-vitro laboratory use only. Not for human or clinical use.
Compound identity
- CAS number: 189691-06-3
- Molecular formula: C₅₀H₆₈N₁₄O₁₀S
- Molecular weight: 1025.22 Da
- Sequence: Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH
- Solubility: Soluble in water at ≥1 mg/mL
- Reconstitution: Add 1 mL bacteriostatic water per 10 mg; swirl gently
For in-vitro laboratory research use only. Not for human or veterinary use, consumption, or therapeutic application. No medical claims are made.